Navigation Links
Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
Date:9/19/2011

e of breast cancer recurrence at 17 months of median follow-up in patients treated with the AE37 peptide vaccine in the ongoing trial. The authors concluded that the AE37 vaccine is safe and well-tolerated with the ability to generate sustained, robust in vitro and in vivo immune response in vaccinated breast and prostate cancer patients.

"We are pleased to see that as the data from clinical trials accumulate, AE37 continues to show that it is not only on track to achieve a positive endpoint in the treatment of breast cancer, but also shows clear advantages over other peptide and cancer vaccine strategies," said Eric von Hofe, Ph.D., President of Antigen Express.  "The clinical path forward for AE37 is straightforward, with the Phase III trial designed and ready to be implemented."

Per trial design in the ongoing Phase II study, patients are being followed for clinical recurrences; data regarding the efficacy of the AE37 vaccine will be reported after a median follow-up of 24 months. Antigen Express anticipates being able to hold an end of Phase II meeting with the FDA in the second half of 2012, followed by initiation of a pivotal Phase III trial. The company is currently seeking a partner for Phase III development and commercialization.

About AE37

Antigen Express' novel Ii-Key Hybrid Preventive HER-2/neu Peptide Vaccine (AE37) is an "off-the-shelf" cancer immunotherapy product candidate that is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a fragment of the HER2 oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER-2 expression who are not eligible for treatment with trastuzumab (Herceptin®).  Only 25% of breast ca
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Provides Update on Spinout of Antigen Express
2. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
3. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
6. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
7. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
8. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
9. Medicago succesfully expresses VLP antigen for A H1N1 strain
10. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
11. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... LLC has been awarded a Phase I Small Business ... Institute on Aging. The project is focused on identifying ... (fat) that are regulated by a calorie restricted ... at LifeGen, the technology developed under the NIH ...
... In honor of National Chemistry Week (NCW), ... in San Diego, California, has joined with Herbert Hoover ... of chemistry in our everyday lives. National ... American Chemical Society (ACS) to unite local ACS ...
... Md., Oct. 21 United Therapeutics Corporation (Nasdaq: ... its third quarter 2010 financial results before market open ... will host a half-hour teleconference on Thursday, October 28, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. ...
Cached Biology Technology:LifeGen Technologies Awarded NIH Grant to Identify Biomarkers of a Calorie Restricted Diet in Adipose Tissue 2MicroConstants Celebrates National Chemistry Week by Teaching San Diego High School Students About the Drug Development Process 2
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday ... biometrics industry as Acuity Market Intelligence reports that ... finally be open. Acuity forecasts that intensifying demand ... that incorporate biometrics will drive a global market ... biometric devices by 2020.   According ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... suggest that policy makers examine greenhouse gas (GHG) ... sources must be rapidly replaced by windmills, solar ... recommendations could be used to help policy makers ... will optimize greenhouse gas emission reductions., "The energy ...
... scientists from Princeton University and The Cancer Institute of New ... the secret lives of cancer cells that go dormant and ... produce new cancer therapies to stem changes that render cancer ... know: What role is this self-cannibalization playing in the middle ...
... aerospace and ocean engineering at Virginia Tech, is the latest ... a National Science Foundation (NSF) Faculty Early Career Development (CAREER) ... 70 Virginia Tech CAREER award winners, of which some 60 ... award was created in 1994. He will receive some $400,000 ...
Cached Biology News:Queen's researchers propose rethinking renewable energy strategy 2Research team targets self-cannibalizing cancer cells 2Research team targets self-cannibalizing cancer cells 3Research team targets self-cannibalizing cancer cells 4Research team targets self-cannibalizing cancer cells 5Engineer studies tensional integrity of biological structures 2Engineer studies tensional integrity of biological structures 3
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
...
Mouse Amphiregulin MAb (Clone 206220)...
Biology Products: